AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
chenodiol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4361 | 474-25-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 0.19 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 5.70 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.42 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,CDK5,EIF2AK3,ERBB2,GRK2,ITK,MAPK7,NTRK2,PDK1,PDK2,PDK4,PRKDC,TEK | 13 | |||
| kinase-selectivity-class | EIF2AK3,GRK2 | 2 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 28, 1983 | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A05AA01 | ALIMENTARY TRACT AND METABOLISM BILE AND LIVER THERAPY BILE THERAPY Bile acids and derivatives |
| FDA CS | M0002475 | Bile Acids and Salts |
| MeSH PA | D002400 | Cathartics |
| MeSH PA | D005765 | Gastrointestinal Agents |
| FDA EPC | N0000175802 | Bile Acid |
| CHEBI has role | CHEBI:53784 | antispasmodic drug |
| CHEBI has role | CHEBI:75771 | mouse metabolite |
| CHEBI has role | CHEBI:77746 | human metabolite |
Related Drugs by ATC class:
A05AA Bile acids and derivatives 4 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Calculus in biliary tract | indication | 266474003 | |
| Hypercholesterolemia | contraindication | 13644009 | |
| Obstruction of bile duct | contraindication | 30144000 | |
| Primary biliary cirrhosis | contraindication | 31712002 | DOID:12236 |
| Diarrhea | contraindication | 62315008 | |
| Liver function tests abnormal | contraindication | 166603001 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Sclerosing cholangitis | contraindication | 235917005 | DOID:14268 |
| Pregnancy, function | contraindication | 289908002 | |
| Gallstone Complications | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.92 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 250MG | CTEXLI | MIRUM | N219488 | Feb. 21, 2025 | RX | TABLET | ORAL | Feb. 21, 2028 | NEW PRODUCT |
| 250MG | CTEXLI | MIRUM | N219488 | Feb. 21, 2025 | RX | TABLET | ORAL | Feb. 21, 2032 | TREATMENT OF CEREBROTENDINOUS XANTHOMATOSIS (CTX) IN ADULTS |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Bile acid receptor | Nuclear hormone receptor | AGONIST | EC50 | 5.47 | CHEMBL | CHEMBL | |||
| fMet-Leu-Phe receptor | GPCR | ANTAGONIST | Ki | 4 | IUPHAR | ||||
| G-protein coupled bile acid receptor 1 | GPCR | AGONIST | EC50 | 5.40 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| 0GEI24LG0J | UNII |
| 4022365 | VUID |
| D00163 | KEGG_DRUG |
| N0000146754 | NUI |
| 4018428 | VANDF |
| 4022365 | VANDF |
| C0008024 | UMLSCUI |
| CHEBI:16755 | CHEBI |
| JN3 | PDB_CHEM_ID |
| CHEMBL240597 | ChEMBL_ID |
| 10133 | PUBCHEM_CID |
| DB06777 | DRUGBANK_ID |
| 4391 | INN_ID |
| 2323 | RXNORM |
| 25632 | MMSL |
| d07268 | MMSL |
| 001208 | NDDF |
| 82490009 | SNOMEDCT_US |
| 89132005 | SNOMEDCT_US |
| D002635 | MESH_DESCRIPTOR_UI |
| 608 | IUPHAR_LIGAND_ID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Chenodiol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0722-7121 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 19 sections |
| Chenodal | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68974-876 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 20 sections |
| CTEXLI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 79378-310 | TABLET, FILM COATED | 250 mg | ORAL | NDA | 28 sections |
| Chenodiol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 79739-7121 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 19 sections |